Laboveritas to Introduce TempO-Seq Across Latvia and Lithuania

BioSpyder Technologies, Inc. has entered into a distribution agreement with Laboveritas to expand access to its TempO-Seq™ gene expression profiling technology across Latvia and Lithuania. 

Through the partnership, researchers, laboratories, biotechnology companies, and pharmaceutical organizations in both countries will gain greater regional access to BioSpyder’s transcriptomic solutions, supported by Laboveritas’ local market presence and customer relationships. 

TempO-Seq provides a scalable alternative to conventional RNA sequencing for researchers analyzing large sample cohorts. Its streamlined workflow can process several sample types without requiring RNA extraction or complementary DNA conversion, reducing preparation time and workflow complexity. 

The technology supports applications across toxicology, drug discovery, oncology, environmental health, biomarker research, and translational science. BioSpyder offers whole-transcriptome and targeted gene panels, along with a whole-miRNome assay for high-throughput microRNA profiling. 

The agreement strengthens BioSpyder’s growing European distribution network and introduces TempO-Seq to additional research communities throughout the Baltic region. 

“Partnering with Laboveritas gives BioSpyder an opportunity to build stronger connections with researchers in Latvia and Lithuania,” said Garrett McComb, Director of BioSpyder Technologies. “We look forward to helping more laboratories adopt scalable gene expression profiling tools for their research programs.” 

BioSpyder and Laboveritas will work together to introduce the platform to regional customers, provide commercial and technical coordination, and help researchers identify the most appropriate TempO-Seq panels and services for their studies. 

For more information about TempO-Seq and BioSpyder’s gene expression profiling technologies, visit www.biospyder.com.